Arcutis Biotherapeutics (ARQT) EBT (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly EBT of -$11.2 million for Q1 2026, up 54.8% year-over-year from -$7.2 million in Q1 2025, and down 162.7% quarter-over-quarter from $17.9 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) EBT (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' EBT history runs 8 years deep, the most recent figure standing at -$11.2 million for Q1 2026.
- In Q1 2026, EBT rose 54.8% year-over-year to -$11.2 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 98.92% YoY), while the FY2025 annual figure was -$15.0 million, up 89.26% from the prior year.
- EBT for Q1 2026 stood at -$11.2 million, down from $17.9 million in the prior quarter.
- The five-year high for EBT was $17.9 million in Q4 2025, with the low at -$107.7 million in Q3 2022.
- The 5-year median for EBT is -$41.7 million (2023), against an average of -$43.4 million.
- The sharpest annual moves came in 2022 and 2025: EBT plunged 88.76% in 2022, then soared 270.71% in 2025.
- Arcutis Biotherapeutics' EBT stood at -$72.0 million in 2022, then grew by 8.0% to -$66.3 million in 2023, then jumped by 84.21% to -$10.5 million in 2024, then jumped by 270.71% to $17.9 million in 2025, then plunged by 162.7% to -$11.2 million in 2026.
- Business Quant data shows ARQT's EBT at -$11.2 million in Q1 2026, $17.9 million in Q4 2025, and $7.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 15.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.15 Mn |
| Mar 31, 2026 | -11.20 Mn |
| Dec 31, 2025 | 17.87 Mn |
| Sep 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | -15.54 Mn |
| Mar 31, 2025 | -24.78 Mn |
| Dec 31, 2024 | -10.47 Mn |
| Sep 30, 2024 | -41.54 Mn |
| Jun 30, 2024 | -52.33 Mn |
| Mar 31, 2024 | -35.06 Mn |
| Dec 31, 2023 | -66.26 Mn |
| Sep 30, 2023 | -41.74 Mn |
| Jun 30, 2023 | -70.99 Mn |
| Mar 31, 2023 | -80.10 Mn |
| Dec 31, 2022 | -72.02 Mn |
| Sep 30, 2022 | -107.71 Mn |
| Jun 30, 2022 | -68.06 Mn |
| Mar 31, 2022 | -65.23 Mn |
| Dec 31, 2021 | -71.64 Mn |
| Sep 30, 2021 | -57.06 Mn |